ClinConnect ClinConnect Logo
Search / Trial NCT01432873

Oral Selenium Therapy for the Prevention of Mucositis

Launched by TEHRAN UNIVERSITY OF MEDICAL SCIENCES · Sep 12, 2011

Trial Information

Current as of July 22, 2025

Unknown status

Keywords

Bmt Hsct

ClinConnect Summary

Patients with AML or ALL diagnosis, candidates for high dose chemotherapy with stem cell transplantation will be screened for enrollment in the study.

Patients will be randomized in two groups with balanced block randomization method. One group will receive selenium tablet twice per day and another group will receive placebo two times per day.Therapy will start on the morning before starting chemotherapy and will continue until the first of either discharge day or day +21.

Response assessment will include:

1. Mucositis assessment using WHO grading and OMAS scores- to be done from baselin...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients with AML or ALL undergoing high dose chemotherapy with stem cell transplantation
  • Adequate renal and hepatic function
  • Exclusion Criteria:
  • Taking selenium supplement before admission

About Tehran University Of Medical Sciences

Tehran University of Medical Sciences (TUMS) is a prestigious institution dedicated to advancing healthcare through innovative research and education. As a leading clinical trial sponsor, TUMS is committed to conducting high-quality, ethically sound clinical research that contributes to the understanding and treatment of various medical conditions. With a strong emphasis on collaboration and interdisciplinary approaches, TUMS harnesses the expertise of its diverse faculty and state-of-the-art facilities to facilitate groundbreaking studies that aim to improve patient outcomes and enhance public health. Through its rigorous oversight and adherence to regulatory standards, TUMS ensures the integrity and reliability of its clinical trials, fostering trust and transparency in the research community.

Locations

Tehran, , Iran, Islamic Republic Of

Patients applied

0 patients applied

Trial Officials

Molouk Hadjibabaie, Pharma D

Study Chair

Tehran University of Medical Sciences

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials